(509) 228-1000 WA
(208) 754-3100 ID

Recent medical advancements in oncology care are enhancing outcomes for cancer patients. Optune, a new, leading-edge treatment for glioblastomas (GBM), is helping to pave the way, resulting in minimal side effects and better quality of life for those who receive it.

A group of Cancer Care Northwest (CCNW) physicians, Medical Oncologists Dr. Robert Gersh and Dr. Srivalli Gopaluni, and Radiation Oncologists Dr. Christopher Lee, Dr. Jason Call, Dr. Stephen Thatcher, Dr. Aaron Wagner, Dr. Robert Fairbanks, and Dr. Wayne Lamoreaux, are certified providers. Offering this new cutting-edge technology will enhance the quality of local medical care, and add another component to the cancer-fighting treatment array CCNW provides. Cancer Care Northwest is the first to offer this leading-edge treatment in all of Eastern Washington, as well as Idaho State.

Optune is a portable device that delivers treatment through ceramic discs within an adhesive bandage called “transducer arrays.” These discs are placed directly on the scalp, allowing the arrays to directly target the brain tumor. Optune then creates alternating “wave-like” electrical fields called Tumor Treating Fields (TTF) that travel across the upper part of the brain in different directions to help slow or stop GBM cancer cells from dividing.  For more information on Optune, please visit www.optune.com

 

Optune is designed specifically to treat glioblastomas (GBM), a type of primary brain cancer. 

“Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM)."

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery and completion of radiation therapy together with concomitant standard of care chemotherapy.

For the treatment of recurrent GBM, Optune is indicated following histologically-or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.” (www.optune.com, 2015).

To learn more about whether Optune is the right treatment for you, please discuss this with your oncology provider, and/or call (509) 228-1000 to speak with a specialized physician. 

On July 13, 2016, Novocure annouced the release of the second generation Optune system, designed to make treatment with Tumor Treating Fields (TTFields) more convenient and manageable for glioblastoma patients. This new system features a TTFields generator that is less than half the weight and half the size of the generator in the first generation Optune system. Including its battery, the second generation Optune system weighs 2.7 pounds, compared to the first generation system weight of 6 pounds. Novocure reduced the weight and size of Optune by utilizing novel digital signal generation technology.

Additional improvements include:

  • easy-grip texture that allows for better handling
  • a battery indicator that displays power and alerts patients when to change the battery
  • a light-detecting sensor that auto-dims the device and charger in the dark
  • and a “No-Stop Swap” feature that enables patients to change batteries or power source without disrupting delivery of TTFields therapy

Novocure will offer existing Optune patients in the United States the opportunity to upgrade to the second generation Optune system over the next several weeks. Moving forward, all new patients will receive the second generation Optune system.

For more information, please visit www.novocure.com.